Rituximab treatment of adults with primary focal segmental glomerulosclerosis

To evaluate the efficacy and safety of rituximab (RTX) in the treatment of primary focal segmental glomerulosclerosis (FSGS) in adults. The clinical data of patients with primary FSGS who received RTX treatment in the First Affiliated Hospital of Zhengzhou University were analyzed retrospectively. T...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2023-04, Vol.13 (1), p.6740-6740, Article 6740
Main Authors: Wang, Liuwei, Yu, Lu, Wang, Yulin, Guo, Yanhong, Zhai, Zihan, Tang, Lin
Format: Article
Language:English
Subjects:
631/250/1619/40/1906
692/699/1585/2759/1523
Adult
End-stage renal disease
Glomerulosclerosis, Focal Segmental - complications
Glucocorticoids
Glucocorticoids - therapeutic use
Humanities and Social Sciences
Humans
Immunosuppressive agents
Immunotherapy
Kidney diseases
Lymphocytes B
Male
Monoclonal antibodies
multidisciplinary
Nephrotic syndrome
Nephrotic Syndrome - complications
Nephrotic Syndrome - drug therapy
Patients
Peripheral blood
Recurrence
Remission
Remission (Medicine)
Retrospective Studies
Rituximab
Rituximab - adverse effects
Science
Science (multidisciplinary)
Treatment Outcome
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the efficacy and safety of rituximab (RTX) in the treatment of primary focal segmental glomerulosclerosis (FSGS) in adults. The clinical data of patients with primary FSGS who received RTX treatment in the First Affiliated Hospital of Zhengzhou University were analyzed retrospectively. The selected patients received RTX twice or four times, with a single dose of 375 mg/m 2 , and the interval between two times of administration of RTX was 2–4 weeks. The treatment target is to achieve the clearance of B cells (peripheral blood B cell count 
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-023-33678-y